Filter News

AusCann Makes Major Process Towards Production of Cannabinoid Medicines during FY18

Published: Sep 07, 2018

Highlights

  • Undertook comprehensive pharmaceutical development project to create an optimal dosage from cannabinoid medicine
  • Signed an agreement with Australia's leading distributor of pharmaceutical products
  • Established a medical outreach program to ensure Australian doctors have access to the necessary information required to prescribe medical cannabis products
  • Completed a second harvest in Chile, with a significant increase in yield
  • Appointed a Master Grower and entered a cultivation research agreement with Canadian group Jade Cannabis
  • Welcomed the Federal Government's decision to allow the export of manufactured cannabinoid medicines from Australia
  • Raised over A$35m post FY18 and is well-funded to continue executing strategic goals

Friday, 31 August 2018 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’)  is pleased to provide its preliminary results for the financial year ended 30 June 2018.

To read the ASX anouncement, please click here

To read the Appendix 4E and Preliminary Final Report, please click here

To unsubscribe, please click here: Unsubscribe

 

About AusCann Group Holdings Limited

AusCann Group Holdings Limited (ASX:AC8) is an Australian-based pharmaceutical company that aims to produce high quality, economical, and clinically validated cannabinoid medicines. Auscann is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products. Through partnerships with industry experts, existing leading market participants and doctors, AusCann is building operations and educating the medical community about the benefits of cannabinoid medicines. Incorporated in 2014, AusCann is currently the only company with the full set of necessary licenses to grow and manufacture cannabinoid medicines in Australia. The company is initially targeting medications for neuropathic and chronic pain in Australia and Chile, whilst exploring global export opportunities.

 

Copyright © 2018 AusCann Group Holdings Limited, All rights reserved.

Our mailing address is:

Suite 8, Level 2, 57 Shenton Avenue, Joondalup Western Australia 6027 Australia

 

Back to news